1.

2.
3.
4.
5.
6.
7.
8.
9.
10.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

1.
2.
3.
4.
5.
6.
7.

8.
9.
10.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

QSPM for VitaVerde Pharmaceu

Opportunities
The population is growing by 1.59% each year
Less government spending on healthcare (only 7%)
40% of the children born with Ciprofloxacin resistance
Number of Patient increasing by significant rates
Strategic Placement: Bold & Innovative alliances with natives
Exclusive 5-year contract with (HEMC) that competitors lack
Ten year tax exemption benefit due to Industrial set up in EPZ
Benefits of free samples for children to unemployed parents
Transportation channel has increased by 30%
No IPR rule till imposed for pharmaceutical industry.
Threats
High competition because of many players in the industry
Regulations are rapidly changing to cover govt's defecit finance
Political Instability (Strikes, Blockades and others)
Unexpected currency fluctuations due to political instability
Termination of a partnership
Competitors are craving for new technology
Chances to fall victim to hostile takeover by market leaders like Square/Beximco
Market leaders dominate in terms of raising capital
Competitive advantages like R&D and Technology are not eternal
Increased Cost of R&D
Strengths
Cashflows increased
Inventory turnover raised from 3.8 to 4.2
Product variation (almost 200 generics of medicines)
Strict company ethics
Shareholder-friendly Dividend Policy
Strong Employee morale
2 R&D specialists hired from MIT

Television Advertising expenditure decreased by 11%

Patient & Prescription Assistance Program
Revenures per employee increased by 22%
Weaknesses
Lack of Biologists
Overreliance on single product (Azitrhroximicin)
Reduced foreign exports
Chemical labs require upgradation
Inadequate vehicles for on-time delivery
Installment of 3 mechineries necessary
Office Building needs new painting, carpets and other furnitures
Too much dependence on foreign imports for raw-materials
Lower market share than Renata, Opsonin and Beximco
Outlets are few and locations are remote
TOTALS

armaceuticals
Improve current
production base
to increase
productivity level

Add new
manufactureing
plants and
product variety

Weight

AS

TAS

AS

TAS

0.05

0.20

0.10

0.05

0.20

0.10

0.05

0.20

0.05

0.05

0.20

0.10

0.05

0.00

0.00

0.05

0.00

0.00

0.05

0.10

0.15

0.05

0.00

0.00

0.05

0.10

0.05

0.05

0.15

0.10

0.05

0.05

0.10

0.05

0.00

0.00

0.05

0.00

0.00

0.05

0.00

0.00

0.05

0.00

0.00

0.05

0.10

0.05

0.05

0.20

0.15

0.05

0.20

0.10

0.05

0.15

0.10

0.05

0.10

0.05

0.10

0.40

0.30

0.05

0.15

0.20

0.05

0.10

0.20

0.01

0.00

0.00

0.02

0.00

0.00

0.02

0.00

0.00

0.05

0.10

0.20

0.10
0.05
0.05

3
0
3

0.30
0.00
0.15

2
0
2

0.20
0.00
0.10

0.06

0.18

0.24

0.05

0.15

0.20

0.03

0.12

0.06

0.05

0.20

0.05

0.05

0.20

0.10

0.05

0.20

0.05

0.02

0.08

0.04

0.05

0.15

0.10

0.07

0.28

0.14

0.07

0.21

0.07

4.92

3.45